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Thehe American College of Cardiology (ACC) and American Heart Association
(AHA) practice guidelines (dating back to 1998) propose early anticoagula-
tion with warfarin as a class I recommendation in patients with biologic
rosthetic heart valves, with a target international normalized ratio (INR) of 2.5 to
.5, during the first 3 months from the implant. The guidelines do not make any
istinction among type of prosthesis (biologic or mechanical) or site of implant.E1
The first 3 postoperative months are classically considered a high-risk time
nterval for thromboemboli formation, as long as the process of endothelialization of
ewing ring and sutures reaches completion.E2 Biologic valves have been recog-
ized to be at lower risk when compared with mechanical valvesE3; among them,
ortic bioprostheses show inferior thrombogenicity than mitral bioprostheses.E4
Last year, the CTSNet Valve Technology Center released the results of its
tudy,E5 which focused on the early antithrombotic regimen adopted by CTSNet
urgeons members, after aortic tissue valve replacement. The study intended to
stablish the level of awareness of the ACC/AHA guidelines among the 726
articipating surgeons and the adherence to the guidelines in their daily practice. In
ach country (mainly the United States and Europe), the percentage of respondents
cquainted with or unaware of the guidelines were equally distributed, with an
verall prevalence of awareness (79% vs 21%).
Three main issues emerged from the study:
1. More than 60% of surgeons are convinced that oral anticoagulation therapy
administration prolongs hospital stay of approximately 2 to 3 days.
2. More than 60% believe that antiplatelet therapy alone represents a valuable
alternative, in absence of comorbidities, granting patients safety and reducing
overall stay and cost of care; they no longer consider warfarin to be the gold
standard of early antithrombotic therapy for biologic valves.
3. Approximately 50% of surgeons adopt antiplatelet therapy in their current
practice instead of warfarin in 90% of patients without comorbidities.
At the opposite end of the spectrum, more than 25% of surgeons not only
dminister warfarin after aortic tissue valve replacement but also maintain long-term
nticoagulant therapy, even in the absence of comorbidities.
The emerging issue is that surgeons are not comfortable with the current
ecommendations and are experimenting with experiencing alternative options.
articipating surgeons showed a weak compliance with early anticoagulation ther-
py prescribed by guidelines, which is mainly related to the intrinsic limits of
icumarolic therapy, such as the need for strict INR monitoring, with progressive
osage adjustment until anticoagulation optimization is achieved, as well as the
onstant risk of bleeding.E6 Antiaggregant therapy with aspirin represents an easy
lternative and has been adopted by more than 50% of surgeons, with an actual constant
rend diverging from the recommendations.E7-8 Nevertheless, evidence-based medicine
equires proven results before modifying an established practice and adopting new
herapeutic strategies.
In an article entitled “Aspirin or Coumadin as the Drug of Choice for Valve
eplacement with Porcine Bio-prosthesis,” Nunez and colleaguesE9 launched a
amlet-like dilemma. The study was limited by its retrospective character and
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1eterogeneous patient population (patients undergoing aor-
ic, mitral, or double-valve surgery, either in sinus rhythm or
trial fibrillation). Nevertheless, the results outline the absence
f thromboembolic complications in patients in sinus rhythm,
egardless of whether they received an antiplatelet or antico-
gulation regimen. On the other hand, a statistically significant
igher prevalence of hemorrhagic complications occurred in
atients receiving warfarin.
Ten years later, in a retrospective review, Blair et alE10
eported a similar rate of thromboembolic complications
fter valve replacement with aortic pericardial bioprostheses
n patients receiving aspirin (0.8%  0.2% patients/year),
arfarin (2.9%  1.6% patients/year), or no therapy (1.5%
0.6% patients/year).
In another retrospective trial, Moinuddeen and col-
eaguesE11 claimed that anticoagulation therapy after bio-
ogic aortic valve replacement is unnecessary. In fact, even
f no increase in postoperative rate bleeding or in prolonged
ospitalization was registered in anticoagulated patients,
urvival was not affected by the exclusion of any antithrom-
otic therapy.
This article was published in the following issue of the
ame journal reporting the ACC/AHA practice guidelines,
epresenting a clear attempt of questioning the guidelines
nd the existence of different policies in clinical practice.
iclopidine therapy has also been proposedE12 as an effec-
ive alternative for thromboembolism prevention (linearized
ncidence of 0.5% patients/year vs 3% patients/year in those
eceiving Coumadin, P  .001), unfortunately encumbered
y a high rate of hemorrhagic events (0.75% patients/year).
As Vaughan et al remarks,E13 in the consensus report of
001, the position of the American College of Chest Physi-
ians regarding antithrombotic early management of biopros-
heses in aortic position was less strict compared with the
osition of the AHA/ACC, indicating 3 months of postopera-
ive anticoagulation as a Grade 2C recommendation. Never-
heless, at the same time, a goal INR of 2.5 (and we wonder
ow this can be reached without vitamin K antagonist therapy)
uring the first 3 months was suggested for both aortic and
itral valves by the American College of Chest Physicians as
Grade A1 recommendation.E14,E15 More recently, the 7th
CPP conference recommended either vitamin K antagonists
Grade 2C) or aspirin (Grade 1C) as antithrombotic prophy-
axis during the first 3 months after aortic bioprosthetic im-
lant. On the basis of observational trials, the evidence for
nticoagulation therapy’s requirement for aortic tissue valves is
eaker compared with that for mitral valves. Nevertheless, the
pportunity to alternatively adopt an antiplatelet therapy is not
upported by firm and undisputable evidence. Convincing data
ow support the adoption of aspirin after aortic valve replace-
ent with biologic valves and may lead to guidelines revisi-
ation. Gherli and associatesE16 conducted a prospective eval-
ation on 275 consecutive patients in sinus rhythm who r
223.e2 The Journal of Thoracic and Cardiovascular Surgery ● Jeceived aspirin or warfarin postoperatively according to the
urgeon’s personal preferences. Warfarin did not confer further
dvantages in terms of stroke-free and overall survival.
A retrospective, large analysis focusing on postoperative
erebral adverse events after tissue aortic valve surgery
onfirmed the absence of added benefit from early antico-
gulation adoption.E17 In the discussion of the article, it is
ointed out that a large randomized study would be required
o exclude the necessity of anticoagulation in the first 3
onths after the implant, but it seems that the current
ractice is advancing faster than the literature. Antiplatelet
herapy is imposing as a widely accepted alternative, as a
fait accompli,” with an evident tendency to abandon the
stablished guidelines, which might not be as safe for sur-
eons as for patients. In fact, as admitted by Sundt and
olleagues, guidelines are no longer only a reference advice
or the daily medical practice, but in case of legal litigation
hey represent a written law we might be accused to have
nconveniently dismissed.
Taking this in consideration, as we have already high-
ighted,E18 we believe that mere clinical evaluation of post-
perative neurologic complications in patients treated with
ntiplatelet therapy instead of warfarin may be restrictive. In
act, microembolization phenomena might not be clinically
vident, and their occurrence might not be excluded on the
asis of neurologic evaluation. Cerebral computed tomog-
aphy scan would probably provide the most exhaustive
nformation, but cost and patients’ radiography exposition
imit its wide use as a screening test. Instead, we propose a
arallel clinical observation and evaluation of microembolic
ignals through the transcranial Doppler (TCD), a noninva-
ive ultrasound examination.
TCD Doppler microembolic signals, called high-intensity
ransient signals (HITS), were first identified in the late
990s during coronary surgery performed using extracorpo-
eal circulation.E19 A causal relation to postoperative cog-
itive dysfunction with possible deterioration of both work-
ng and episodic memory has been hypothesized.E20
HITS have been detected during the first 6 months after
alve surgery with mechanical prostheses, even if different
athophysiologic mechanisms have been claimed to be in-
olved in their genesis. HITS detected in recipients of
echanical valves have been interpreted as the Doppler
hotograph of cavitation phenomena with gas bubble for-
ation generating at the valve closure.E21 Neoformed gas-
ous microbubbles would be responsible for the platelets’
ctivation and subsequent hypercoagulability state, expos-
ng patients to a higher risk of thromboembolic acci-
ents.E22 Furthermore, concomitant independent formation
f thrombotic aggregates cannot be excluded. On the con-
rary, HITS have rarely been reported in bioprostheses

























































di Marco, Giordan, Gerosa Editorialsot be addressedE25; instead, transient solid embolization
ay offer a reasonable explanation.
At this point, HITS detection may be useful to investi-
ate any possible difference in solid microembolization
uring the first 3 postoperative months, which are tradition-
lly believed to be the high-risk period for thromboembolic
omplications.E26
Because some thromboembolic phenomena may be clini-
ally irrelevant, we believe that a clinical neurologic evaluation
ssociated with TCD screening for HITS detection during the
arly postoperative period may be a reliable support to a
eaningful comparison of the neurologic course in patients
ndergoing different antithrombotic drug regimens. For this
eason, at our institution we evaluated HITS occurrence
fter valve replacement surgery. In the subcohort of aortic
ioprostheses recipients receiving aspirin instead of warfa-
in, who were free from neurologic complications, no HITS
ere detected at TCD. Subsequently, we decided to resume
he study randomizing patients to anticoagulant or antiplate-
et therapies and evaluating HITS occurrence in all, with
ncouraging preliminary results that will be available soon.
On the basis of our experience, we believe that TCD may be
valuable tool to complete the information gained through
eep neurologic clinical examination, further increasing the
ikelihood of an uneventful postoperative course. We are con-
inced that the firm instrumentation-based evidence offered
y TCD is crucial for an aware patient’s antithrombotic
anagement, especially when practice differs from estab-
ished guidelines.
We must remain aware that guidelines will not change
ecause cardiac surgeons simply choose different ways
rom those suggested, but because enough evidence is pro-
ided to support alternative therapeutic policies.
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